Antios Therapeutics Inc.
Fixed-dose combination antivirals for hepatitis B (ASPIN + nucleoside analogue in single daily pill)
- Sector
- Biotech
- Headquarters
- MENDHAM, NJ
- Founded
- 2018
- Latest Form D
- $75M, Nov 2021
- Total capital
- $126M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $126M
- 4 Form D · last Nov 2021
- 59 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 7 pending · first 2022
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$75M
- Private capital raisedForm D · SEC · 3rd filing$32M
- Private capital raisedForm D · SEC · 2nd filing$4.4M
- Private capital raisedForm D · SEC · 1st filing$15M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Abel De La RosaDirectorNamed in SEC Form D filings
- Benjamin RovinskiDirectorNamed in SEC Form D filings
- Craig GordonDirectorNamed in SEC Form D filings
- David CannerDirectorNamed in SEC Form D filings
- Douglas MayersExecutive OfficerNamed in SEC Form D filings
- Gregory MayesExecutive Officer, DirectorNamed in SEC Form D filings
Show all 14 people
- Henry Lin ChenDirectorNamed in SEC Form D filings
- Idean MarvastyExecutive OfficerNamed in SEC Form D filings
- Iyona RajkomarDirectorNamed in SEC Form D filings
- Nicole VitulioDirectorNamed in SEC Form D filings
- Nicole VitulloDirectorNamed in SEC Form D filings
- Patrick HigginsDirectorNamed in SEC Form D filings
- Scott MorensteinDirectorNamed in SEC Form D filings
- Tamra AdamsExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 9- GrantedOxalamido-substituted Tricyclic Inhibitors Of Hepatitis B VirusUSPTOUS 12,465,590
- PendingInhibitors Of Hepatitis B VirusUSPTOApplication 17937841
- GrantedTricyclic Inhibitors Of Hepatitis B VirusUSPTOUS 11,504,382
Show all 9 patent records
- Oxalamido-substituted Tricyclic Inhibitors Of Hepatitis B VirusNov 11, 2025 · US 12,465,590Granted
- Inhibitors Of Hepatitis B VirusMar 9, 2023 · Application 17937841Pending
- Tricyclic Inhibitors Of Hepatitis B VirusNov 22, 2022 · US 11,504,382Granted
- Pharmacokinetics And Dose-related Improvments In Subjects Treated With Phosphoramidate Clevudine ProdrugsApplication PCTUS2022031287Pending
- Compositions And Methods Of Treating Hepatitis D And Hepatitis B/hepatitis D Co-infections With Phosphoramidate Clevudine ProdrugsApplication PCTUS2022032431Pending
- Improved Synthesis Of Phosphoramidates For The Treatment Of Hepatitis B VirusApplication PCTUS2022031904Pending
- Improved Synthesis Of Phosphoramidates For The Treatment Of Hepatitis B VirusApplication 63196418Pending
- Pharmacokinetics And Dose-related Improvments In Subjects Treated With Phosphoramidate Clevudine ProdrugsApplication 63193925Pending
- Compositions And Methods Of Treating Hepatitis D And Hepatitis B/hepatitis D Co-infections With Phosphoramidate Clevudine ProdrugsApplication 63197565Pending
Related companies, and why
- Nurix TherapeuticsSimilar federal contract value in Biotech · null in contracts
- FIVE ELEVEN PHARMA, INC.Similar federal contract value in Biotech · null in contracts
- Z BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
- aTYR PHARMA INCSimilar federal contract value in Biotech · null in contracts
- Liberation Bioindustries, Inc.Similar federal contract value in Biotech · null in contracts
- EDITAS MEDICINE, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .